GlassScriptPhysician profile
Naeha Gupta
NPI 1588028799
$105,376.63
in general payments reported to CMS, 2019-2025
37 companies · $85K in 2025
The $85K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $282 · 2021: $539 · 2022: $826 · 2023: $1,012 · 2024: $17K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Consulting Fee: $11K · Food and Beverage: $9,936 · Travel and Lodging: $7,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,101.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,245.00 |
| Consulting Fee | $11,216.46 |
| Food and Beverage | $9,935.92 |
| Travel and Lodging | $7,541.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $28,919.73 | 2022-2025 | |
| Leo Pharma INC. | $27,020.93 | 2024-2025 | Anzupgo, Adbry |
| Incyte Corporation | $22,834.35 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $15,560.02 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Janssen Biotech, INC. | $6,578.04 | 2019-2025 | Tremfya |
| Abbvie INC. | $690.50 | 2019-2025 | |
| Amgen INC. | $595.68 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $591.07 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $451.04 | 2022-2025 | |
| Organon LLC | $346.80 | 2025 | Vtama |
| Genzyme Corporation | $253.20 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $243.19 | 2021-2025 | Siliq, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $201.51 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $107.22 | 2025 | Ebglyss, Taltz |
| Celgene Corporation | $105.22 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.